Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, recently provided an update sharing significant milestones reached in 2021 for both of its operating arms, MINDCURE Research and MINDCURE Technology. MINDCURE Research offered several updates, including important milestones in its synthetic ibogaine manufacturing; the company is currently on schedule to provide Good Laboratory Practice (“GLP”) ibogaine to its research partners by the second quarter of 2022. In addition, a pre-clinical update from MINDCURE confirms that it intends to send ibogaine material to its pre-clinical research partner. Initially, the product will be used for broad cardiac and neurological screens with in-depth behavioral studies possible later on. In addition to this pre-clinical trial, MINDCURE has completed the draft research protocol for The Desire Project. “We are proud to report that MINDCURE’s core research programs are progressing rapidly, showcasing our disciplined commitment to advancing MINDCURE’s drug research and commercial production programs,” a recent article quotes MINDCURE President and CEO Kelsey Ramsden as saying. “Concurrently, we maintain a focus on identifying opportunities to expand our drug development pipeline.”
To view the full article, visit https://ibn.fm/4lNFP
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
